Drugs / ASP7147
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01896583 | Nov 2013 → Mar 2014 | irritable bowel syndrome | Seldar Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP7147 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01896583 ↗ |
| Route | Oral | “300 mg, tablet, twice per day for 4 weeks oral” NCT01896583 ↗ |